Capricor Therapeutics (CAPR) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.73
- Estimate
- -$0.41
- Surprise
- -78.6%
- Score today
- 4.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Capricor Therapeutics (CAPR) reported a wider loss than forecast — adjusted EPS of -$0.73 against the -$0.41 estimate (a 78.6% shortfall).
Coverage in the report window
- Capricor Therapeutics Q3 2026 Earnings Call Transcript — benzinga, 2026-11-10
- Capricor Therapeutics Q3 EPS $(0.73) Misses $(0.05) Estimate — benzinga, 2026-11-10
- Capricor Therapeutics' Deramiocel Cardiac Data Wins Outstanding Research Award — fiscal.ai, 2026-11-09
Where TrendMatrix's rating stands now
TrendMatrix currently rates CAPR Sell at 4.6/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate; this quarter's -78.6% surprise compares with a -37.5% four-quarter average.
What argues against it
- Concentration risk — Pipeline: Deramiocel
- Concentration risk — Supplier: donor hearts
- DATA_ISSUE: analyst_target_implausible (raw $27.00 vs price $8.87 — ratio 3.0×). Rejected, falling back to technical TP.
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.87
- Price target
- $9.86
- Stop
- $8.25
- Upside to target
- +11.2%
Risk check: RSI 72 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-11 — shown for context, not personalized investment advice.
CAPR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $515.7M
- P/E (fwd)
- -6.1
- 52-week range
- $2.96–$40.37
- Off 52-week high
- 78.0%
- RSI (14)
- 72
- Volume vs avg
- 1.32×
- Score today
- 4.6/10